DNA sequencing company Illumina forms GRAIL to develop cancer detection blood test
January 12, 2016
Business Affairs
Rad Oncology
Population Health
Primary Care
Risk Management
By Gail Kalinoski, Contributing Reporter
Touting it as a “significant development in the war on cancer,” Illumina, Inc., formed a new company – GRAIL – to develop a blood-based screening test that could detect early-stage cancers in asymptomatic individuals.
Illumina, based in San Diego and the world’s largest DNA sequencing company, will be the majority owner of GRAIL. Other investors in the company, which has initial funding of more than $100 million, include venture capital firms Arch Venture Partners and Sutter Hill Ventures, Microsoft co-founder Bill Gates and Bezos Expeditions. The company is searching for a CEO, but already has an advisory board of world-class cancer specialists and board of directors.
“We hope today is a turning point in the war on cancer,” Jay Flatley, Illumina CEO and chairman of the board of GRAIL, said in a company statement. “By enabling the early detection of cancer in asymptomatic individuals through a simple blood screen, we aim to massively decrease cancer mortality by detecting the disease at a curable stage.”
Powered by Illumina’s sequencing technology, GRAIL will develop a pan-cancer screening test by measuring circulating nucleic acids in the blood. The plan is to get the cost per test to $1,000 or less and make it available through visits to a doctor or testing center, according to MIT Technology Review.
“The holy grail in oncology has been the search for biomarkers that could reliably signal the presence of cancer at an early stage. Illumina’s sequencing technology now allows the detection of circulating nucleic acids originating in the cancer cells themselves, a superior approach that provides a direct rather than surrogate measurement,” said Dr. Richard Klausner, formerly Illumina CMO and NCI director, and a director at GRAIL.
Genetic Engineering & Biotechnology News reported that GRAIL plans to spend the first year in research and development and launch large-scale clinical tests in 2017, with the goal of delivering a pan-cancer test by 2019 and possibly tests for more targeted cancers like breast and lung cancer even earlier.
“It may be the case that the test is exactly the same,” Flatley said during a conference call with reporters, according to Genetic Engineering & Biotechnology News. “It’s just that we would be applying it in a much more limited way, early on, to specific cancers, whereas in the long run it would be intended to be pan-cancer, and cover as many cancers as the clinical trial demonstrates are effective in diagnosing these early cases.”
Touting it as a “significant development in the war on cancer,” Illumina, Inc., formed a new company – GRAIL – to develop a blood-based screening test that could detect early-stage cancers in asymptomatic individuals.
Illumina, based in San Diego and the world’s largest DNA sequencing company, will be the majority owner of GRAIL. Other investors in the company, which has initial funding of more than $100 million, include venture capital firms Arch Venture Partners and Sutter Hill Ventures, Microsoft co-founder Bill Gates and Bezos Expeditions. The company is searching for a CEO, but already has an advisory board of world-class cancer specialists and board of directors.
“We hope today is a turning point in the war on cancer,” Jay Flatley, Illumina CEO and chairman of the board of GRAIL, said in a company statement. “By enabling the early detection of cancer in asymptomatic individuals through a simple blood screen, we aim to massively decrease cancer mortality by detecting the disease at a curable stage.”
Powered by Illumina’s sequencing technology, GRAIL will develop a pan-cancer screening test by measuring circulating nucleic acids in the blood. The plan is to get the cost per test to $1,000 or less and make it available through visits to a doctor or testing center, according to MIT Technology Review.
“The holy grail in oncology has been the search for biomarkers that could reliably signal the presence of cancer at an early stage. Illumina’s sequencing technology now allows the detection of circulating nucleic acids originating in the cancer cells themselves, a superior approach that provides a direct rather than surrogate measurement,” said Dr. Richard Klausner, formerly Illumina CMO and NCI director, and a director at GRAIL.
Genetic Engineering & Biotechnology News reported that GRAIL plans to spend the first year in research and development and launch large-scale clinical tests in 2017, with the goal of delivering a pan-cancer test by 2019 and possibly tests for more targeted cancers like breast and lung cancer even earlier.
“It may be the case that the test is exactly the same,” Flatley said during a conference call with reporters, according to Genetic Engineering & Biotechnology News. “It’s just that we would be applying it in a much more limited way, early on, to specific cancers, whereas in the long run it would be intended to be pan-cancer, and cover as many cancers as the clinical trial demonstrates are effective in diagnosing these early cases.”
1(current)
You Must Be Logged In To Post A CommentRegisterRegistration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now! |
|
